<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076646</url>
  </required_header>
  <id_info>
    <org_study_id>PH-L19IL2DTIC-04-12</org_study_id>
    <nct_id>NCT02076646</nct_id>
  </id_info>
  <brief_title>A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philogen S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philogen S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with&#xD;
      Dacarbazine in patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, open-label, multi-center, Phase I/II dose escalation study in which cohorts of&#xD;
      3-6 patients with metastatic melanoma will be assigned to receive escalating doses of L19-IL2&#xD;
      in combination with a fixed dose of Dacarbazine.&#xD;
&#xD;
      After definition of MTD and RD during the phase II part of this study, 60 patients with Stage&#xD;
      IV M1a and M1b melanoma will be randomized in a 1:1 ratio to receive open label the&#xD;
      combination treatment at the RD (Arm 1) or DTIC monotherapy (Arm 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2</measure>
    <time_frame>From day 1 to day 21 of Cycle 1 (each cycle is 21-days)</time_frame>
    <description>Establish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: best objective response rate (BORR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of antitumor activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: best objective response rate (BORR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: duration of objective response</measure>
    <time_frame>From week 6 up to 1 year</time_frame>
    <description>Evaluation of the antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: disease control rate</measure>
    <time_frame>At 6 months</time_frame>
    <description>Evaluation of the antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: median progression free survival (mPFS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of the antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: median overall survival and overall survival rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of the antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: safety and tolerability of L19-IL2 in combination with DTIC vs DTIC alone.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Safety evaluation including AEs, SAE and standard laboratory assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: duration of objective response</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: disease control rate</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: median progression free survival (mPFS)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: median overall survival and overall survival rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Metastatic Melanoma Stage IV</condition>
  <arm_group>
    <arm_group_label>Ph I: L19IL2 + DTIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.&#xD;
L19-IL2 will be administered on days 1, 8 &amp; 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II - ARM 1: L19IL2 at RD + DTIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II - ARM 2: DTIC monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L19IL2 - Ph I</intervention_name>
    <description>During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).</description>
    <arm_group_label>Ph I: L19IL2 + DTIC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L19IL2 at RD - Ph II</intervention_name>
    <description>L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.</description>
    <arm_group_label>Ph II - ARM 1: L19IL2 at RD + DTIC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTIC</intervention_name>
    <description>Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).</description>
    <arm_group_label>Ph I: L19IL2 + DTIC</arm_group_label>
    <arm_group_label>Ph II - ARM 1: L19IL2 at RD + DTIC</arm_group_label>
    <arm_group_label>Ph II - ARM 2: DTIC monotherapy</arm_group_label>
    <other_name>DETICENE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years of age, inclusive&#xD;
&#xD;
          2. Must have histologically or cytologically confirmed cutaneous metastatic melanoma&#xD;
             (Stage IV). For the Phase II part only patients with Stage IV M1a or M1b will be&#xD;
             enrolled.&#xD;
&#xD;
          3. Must have measurable disease according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST 1.1) as identified by CT or MRI scan within 28 days before the first study&#xD;
             drug administration.&#xD;
&#xD;
          4. Baseline LDH within normal range&#xD;
&#xD;
          5. Maximal 1 line of previous systemic treatment for metastatic disease (prior adjuvant&#xD;
             melanoma therapy, e.g., IFN, is permitted.&#xD;
&#xD;
          6. For women of childbearing potential, a negative pregnancy test within 72 hours prior&#xD;
             to the first dose of study treatment.&#xD;
&#xD;
          7. Women with reproductive potential must be willing to practice acceptable methods of&#xD;
             birth control during the study and for up to 12 weeks after the last dose of study&#xD;
             medication.&#xD;
&#xD;
          8. Men with reproductive potential must be willing to practice acceptable methods of&#xD;
             birth control during the study and for up to 12 weeks after the last dose of study&#xD;
             medication.&#xD;
&#xD;
          9. Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
         10. Life expectancy of at least three months&#xD;
&#xD;
         11. Adequate organ function: serum creatinine ≤ 1.5 x ULN, total bilirubin ≤ 30 mM/L (or&#xD;
             mg/dL, ≤ 2.0 mg/dL), hepatic transaminases ≤ 2.5 x ULN, alkaline phosphatase ≤ 2.5 x&#xD;
             ULN.&#xD;
&#xD;
         12. ANC count ≥ 1.5 x 10^9/L, platelet count ≥ 100 x 10^9/L, hemoglobin &gt; 9 g/dL&#xD;
&#xD;
         13. Normal 12-lead ECG and normal bidimensional echocardiogram or MUGA&#xD;
&#xD;
         14. All toxic effects of prior therapy must have resolved to grade ≤1 unless otherwise&#xD;
             specified above&#xD;
&#xD;
         15. Willing and able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding female&#xD;
&#xD;
          2. Primary ocular melanoma&#xD;
&#xD;
          3. Primary mucosal melanoma&#xD;
&#xD;
          4. Use of any investigational or other anti-cancer drug within 28 days or 5 half-lives,&#xD;
             whichever is longer, preceding the first dose of DTIC and L19-IL2&#xD;
&#xD;
          5. Prior radiation to a target lesion, unless there has been clear progression of the&#xD;
             lesion since radiotherapy&#xD;
&#xD;
          6. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or&#xD;
             Hepatitis C Virus (HCV) infection&#xD;
&#xD;
          7. History or clinical evidence of brain metastases or leptomeningeal disease&#xD;
&#xD;
          8. Any other malignancy from which the patient has been disease-free for less than 5&#xD;
             years, with the exception of adequately treated and cured basal or squamous cell skin&#xD;
             cancer, superficial bladder cancer, or carcinoma in situ of the cervix&#xD;
&#xD;
          9. Treatment with DTIC within 6 months before start of study&#xD;
&#xD;
         10. Treatment with Ipilimumab within 6 months before start of study&#xD;
&#xD;
         11. Hypersensitivity to DTIC&#xD;
&#xD;
         12. Concomitant use of drugs known to alter cardiac conduction&#xD;
&#xD;
         13. Chronic use of corticosteroids used in the management of cancer or non-cancer-related&#xD;
             illness&#xD;
&#xD;
         14. Unstable or serious concurrent uncontrolled medical conditions&#xD;
&#xD;
         15. Inadequately controlled cardiac arrhythmias including atrial fibrillation&#xD;
&#xD;
         16. History of acute or subacute coronary syndromes including myocardial infarction,&#xD;
             unstable or severe stable angina pectoris&#xD;
&#xD;
         17. Heart insufficiency &gt; grade II NYHA criteria&#xD;
&#xD;
         18. Uncontrolled hypertension&#xD;
&#xD;
         19. Ischemic peripheral vascular disease&#xD;
&#xD;
         20. Active infection or incomplete wound healing.&#xD;
&#xD;
         21. History or evidence of active autoimmune disease.&#xD;
&#xD;
         22. Known history of allergy to intravenously administered proteins/peptides/antibodies&#xD;
&#xD;
         23. History of organ allograft.or allogeneic peripheral blood progenitor cell or bone&#xD;
             marrow transplantation&#xD;
&#xD;
         24. Major trauma including surgery within 4 weeks prior to entering the study.&#xD;
&#xD;
         25. Any underlying medical or psychiatric condition which in the opinion of the&#xD;
             investigator will make administration of study drug hazardous or hinder the&#xD;
             interpretation of study results (e.g. AE).&#xD;
&#xD;
         26. Melanoma patients with BRAF 600 E mutation who are amenable to receive approved&#xD;
             treatments able to extend overall survival.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Garbe, Prof. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen (Germany)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Maio, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Senese, Siena (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin</keyword>
  <keyword>IL2</keyword>
  <keyword>monoclonal</keyword>
  <keyword>antibody</keyword>
  <keyword>cytokine</keyword>
  <keyword>Dacarbazine</keyword>
  <keyword>metastatic</keyword>
  <keyword>melanoma</keyword>
  <keyword>tumor targeting</keyword>
  <keyword>Dose definition</keyword>
  <keyword>L19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

